PCSK9 and atherosclerosis: Inhibition of PCSK9 with SBC-115076 alleviates lipid accumulation and reduces atherosclerosis severity, indicating that PCSK9 inhibition has therapeutic potential in HHcy-driven atherosclerosis [128].